Literature DB >> 1893065

Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.

R B Francis1.   

Abstract

Recent evidence suggests that sickle cell disease (SCD) can be considered a hypercoagulable state, in which both platelet activation and thrombin generation are abnormally increased. Although thrombosis is now known to play an important role in at least one of the vasocclusive complications of SCD, namely stroke, the significance of hypercoagulability in the pathogenesis of vascular occlusion in SCD remains unclear. This review summarizes current evidence regarding platelet, coagulation, and fibrinolytic abnormalities in SCD and their possible role in vascular occlusion. Potential implications for therapy are also discussed.

Entities:  

Mesh:

Year:  1991        PMID: 1893065     DOI: 10.1097/00001721-199104000-00018

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  31 in total

1.  P-selectin-mediated platelet-neutrophil aggregate formation activates neutrophils in mouse and human sickle cell disease.

Authors:  Renata Polanowska-Grabowska; Kori Wallace; Joshua J Field; Lanlin Chen; Melissa A Marshall; Robert Figler; Adrian R L Gear; Joel Linden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-11-11       Impact factor: 8.311

Review 2.  Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.

Authors:  Marilyn J Telen
Journal:  Blood       Date:  2016-01-12       Impact factor: 22.113

Review 3.  Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Authors:  Sharada A Sarnaik
Journal:  Pediatr Radiol       Date:  2005-02-10

4.  Structure-function relations of human hemoglobins.

Authors:  Alain J Marengo-Rowe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2006-07

5.  Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease.

Authors:  Nalini Raghavachari; Xiuli Xu; Amy Harris; Jose Villagra; Carolea Logun; Jennifer Barb; Michael A Solomon; Anthony F Suffredini; Robert L Danner; Gregory Kato; Peter J Munson; Sidney M Morris; Mark T Gladwin
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

6.  Developing new pharmacotherapeutic approaches to treating sickle-cell disease.

Authors:  Marilyn J Telen
Journal:  ISBT Sci Ser       Date:  2016-11-15

Review 7.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

8.  Efficient Quantitative Analysis of Carboxyalkylpyrrole Ethanolamine Phospholipids: Elevated Levels in Sickle Cell Disease Blood.

Authors:  Junhong Guo; Hua Wang; Borys Hrinczenko; Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2016-06-24       Impact factor: 3.739

Review 9.  Interplay between coagulation and vascular inflammation in sickle cell disease.

Authors:  Erica Sparkenbaugh; Rafal Pawlinski
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

10.  Morphological and functional platelet abnormalities in Berkeley sickle cell mice.

Authors:  Arun S Shet; Thomas J Hoffmann; Marketa Jirouskova; Christin A Janczak; Jacqueline R M Stevens; Adewole Adamson; Narla Mohandas; Elizabeth A Manci; Therese Cynober; Barry S Coller
Journal:  Blood Cells Mol Dis       Date:  2008-04-18       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.